StockData
Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc. (PACB) stock analysis

PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$2.09−0.15 (-6.70%)

Close on Nov 11, 2026Market cap $649.64MP/E –Yield 0.00%

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth1Performance1Health1Dividend0

Weak3 of 30 checks passed

Pacific Biosciences of California passes 3 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
1/6
Financial health
1/6
Dividend
0/6

What stands out

  • Gross margin improving

    Gross margin was 34.4% over the last twelve months, against 25.4% a year earlier.

  • Net margin above its 5-year average

    Net margin was -81.3% over the last twelve months, against a 5-year average of -216%.

  • Short-term assets cover short-term debts

    Current assets are 4.62 times current liabilities.

What to watch

  • Revenue growing under 10% a year

    Revenue grew 7.6% a year over the last three fiscal years, short of the 10% we look for.

  • Interest not well covered

    Operating income covers interest expense -17.2 times; we look for at least 5.

  • Elevated bankruptcy risk

    The Altman Z-score is -4.89; above 3 is the safe zone and below 1.8 the distress zone.

  • Guidance lowered

    Pacific Biosciences of California lowered its full year 2026 revenue outlook on Aug 5, 2026.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/S above the industry

    Pacific Biosciences of California's price-to-sales of 4.03 is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 3.99 (book value is negative, so we use sales).

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing under 10% a year

    Revenue grew 7.6% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 4.4% over the last twelve months; the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median is 8.4%.

  • Guidance lowered

    Pacific Biosciences of California lowered its full year 2026 revenue outlook on Aug 5, 2026.

  • Gross margin improving

    Gross margin was 34.4% over the last twelve months, against 25.4% a year earlier.

Past performance1/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -81.3% over the last twelve months, against a 5-year average of -216%.

  • Net margin below the industry

    Pacific Biosciences of California's net margin of -81.3% is below the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of -1.3%.

Financial health1/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest not well covered

    Operating income covers interest expense -17.2 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 4.62 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -4.89; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Pacific Biosciences of California has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Pacific Biosciences of California. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 3.1
  • Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median 3.2

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$39.04M
Value traded per 1% price move
$2.96M

Downside

High risk

Typical loss in a bad month
33.9%
Volatility (annualized)
94%
Sharpe ratio, 1 year
0.15
Beta to the S&P 500 (5Y)
2.20

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

28.6%−12.7 pts over 5 years

Operating margin

-346.2%−213.8 pts over 5 years

Net margin

-341.5%−378.7 pts over 5 years

See a number that looks wrong?